Eriko Koide
Harvard University
4 Papers
Eriko Koide is an academic researcher from Harvard University. The author has contributed to research in topics: Chemistry & Cancer. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo.
Christian Dubiella,Benika J. Pinch,Kazuhiro Koikawa,Kazuhiro Koikawa,Daniel Zaidman,Evon Poon,Theresa D. Manz,Theresa D. Manz,Behnam Nabet,Shuning He,Efrat Resnick,Adi Rogel,Ellen M. Langer,Colin J. Daniel,Hyuk-Soo Seo,Ying Chen,Guillaume Adelmant,Shabnam Sharifzadeh,Scott B. Ficarro,Yann Jamin,Barbara Martins da Costa,Mark W. Zimmerman,Xiaolan Lian,Xiaolan Lian,Shin Kibe,Shin Kibe,Shingo Kozono,Shingo Kozono,Zainab M. Doctor,Christopher M. Browne,Christopher M. Browne,Annan Yang,Liat Stoler-Barak,Richa B. Shah,Nicholas E. Vangos,Ezekiel A. Geffken,Roni Oren,Eriko Koide,Samuel Sidi,Ziv Shulman,Chu Wang,Jarrod A. Marto,Sirano Dhe-Paganon,Thomas Look,Thomas Look,Xiao Zhen Zhou,Xiao Zhen Zhou,Kun Ping Lu,Kun Ping Lu,Rosalie C. Sears,Louis Chesler,Nathanael S. Gray,Nathanael S. Gray,Nir London +53 more
TL;DR: Sulfopin this article, a nanomolar Pin1 inhibitor, was developed to identify covalent inhibitors targeting Pin1's active site Cys113, which achieved potent cellular and in vivo target engagement and phenocopies Pin1 genetic knockout.
110
Exploring the target scope of KEAP1 E3 ligase-based PROTACs.
Guang Yan Du,Jie Jiang,Nathaniel J. Henning,Nozhat Safaee,Eriko Koide,Radosław P. Nowak,Katherine A. Donovan,Hojong Yoon,Inchul You,Hong Yue,Nicholas A. Eleuteri,Zhixiang He,Zhengnian Li,Hubert T Huang,Jianwei Che,Behnam Nabet,Tinghu Zhang,Eric S. Fischer,Nathanael S. Gray +18 more
TL;DR: In this article , the Kelch-like ECH-associated protein 1 (KEAP1) inhibitor KI696 was converted into a recruitment handle for several targets, including the BET family and murine focal adhesion kinase.
47
Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.
Brian J. Groendyke,Behnam Nabet,Mikaela L. Mohardt,Haisheng Zhang,Haisheng Zhang,Ke Peng,Eriko Koide,Calvin R Coffey,Jianwei Che,David A. Scott,Adam J. Bass,Adam J. Bass,Nathanael S. Gray +12 more
TL;DR: A novel series of small molecules based on a tricyclic pyrimidothiazolodiazepinone core that displays both high potency and selectivity for FAK and is a valuable chemical probe for evaluation of FAK-dependent biology.
15
Development and characterization of selective FAK inhibitors and PROTACs with in vivo activity.
Eriko Koide,Mikaela L. Mohardt,Zainab M. Doctor,Annan Yang,Mingfeng Hao,Katherine A. Donovan,Alissa J. Nelson,Kathryn Abell,Jianwei Che,Matthew P. Stokes,Tinghu Zhang,Andrew J. Aguirre,Eric S. Fischer,Nathanael S. Gray,Baishan Jiang,Behnam Nabet +15 more
TL;DR: Li et al. as mentioned in this paper developed a selective FAK inhibitor (BSJ-04-175) and degrader(BSJ04-146) to evaluate the consequences and advantages of abolishing all FAK activity in cancer models.